WITTEN, Germany, October 29 /PRNewswire-FirstCall/ -- The comparative study of chronic wound treatment at the Hospital Civil of Cd. Victoria, Tamaulipas, Mexico, was concluded successfully. Due to the significantly superior therapeutic success the Ministry of Health ordered the control to be abandoned and moved to Hemospray treatment for ethical reasons. 22 of the 24 patients within the Hemospray group were healed completely, while 22 of the 24 patients of the control group showed no comparable progress. Moreover, additional patients suffering from diabetic foot disease were successfully treated with Hemospray. The total healing ratio is significantly higher than 75%.
These results were presented to health system representatives of several Latin American countries in Mexico City by the Chief Investigator of the study.
The results are currently being evaluated by the State Health Authorities of Tamaulipas who sponsored the study.
Apart from this, a considerable share of the patient data were crosschecked and evaluated by Sangui in Witten. It turned out that these data confirm the results as previously indicated. Sangui regards this outcome as a confirmation of the outstanding efforts made by the teams on location and as a great success of its systematic competence in wound healing.
SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: For more information please contact: Joachim Fleing, Phone:
+49(160)741-27-17, Fax: +49(2302)915-191, e-mail: fleing@sangui.de
